Proton pump inhibitor

Peptic ulcer is a common gastrointestinal disease seen among many peoples. It may be caused by irregular food habits, spicy foods, either an infection or long-time use of medications, drugs and stress. An ulcer depends upon the presence of acid and peptic activity in gastric juice plus a breakdown in mucosal defences. A number of anti-ulcer drug are available for curing ulcer disease. Standard treatment is including antibiotics and proton pump inhibitors. But the same time these drugs are expensive and there are many side effects caused by these drugs comparing to other herbal medicines. Pantoprazole is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion. It is used to treat stomach ulcers, gastro-oesophageal reflux disease (GORD), acid reflux, and heartburn. Zollinger-Ellison syndrome is a rare disorder brought on by a pancreatic or intestinal tumour that is treated with pantoprazole. Both a generic and a brand-name version of the oral tablet medication pantoprazole are offered. A stomach H+/K+-ATPase (hydrogen-potassium adenosine triphosphatase) inhibitor is pantoprazole. Although oral dose forms are the most common drug, they nevertheless have significant drawbacks compared to other delivery systems, such as the possibility of medication absorption that is too sluggish and complicated by gastric residence time. It can be treated by using a lesser dosage of the medication instead of taking it in liquid form. Another technique is the effervescent technique, which can be used to create a dosage form that can speed up the time the drug dissolves and combines with the body. This technique is typically employed with preparations for rapid release. Effervescent tablets are being used more frequently and widely to modify the behaviour of drug release, such as in sustained and controlled release preparations, pulsatilla drug delivery systems, and so forth, along with the development of novel pharmaceutical techniques. The present review illustrated about the etiology of peptic ulcer, its complications, pharmacological property of pantoprazole antiulcer drug and the new effervescent tablet methodology.

Pulsatile Drug Delivery systems (PDDS) are basically time-controlled drug delivery systems in which the system controls the lag time and drug is released in an immediate or extended fashion. The present study was conducted to develop and evaluate pulsatile release tablets of Rabeprazole sodium for the treatment of peptic ulcers. The compression coated tablets consisted of a core tablet containing drug with superdisintegrant, which was further coated by erodible outer layer consisted of HPMC K15M, ethyl cellulose and Karaya gum. After carrying out preformulation studies, the developed tablets were evaluated for post-compression parameters like weight variation, thickness, hardness, friability, drug content and in-vitro drug release study. The best formulation was selected on the basis of post-compression parameters and was subjected to accelerated stability studies for 1 month. Amongst 6 formulations prepared, C5 produced convincing results with a maximum cumulative drug release of 99.97% in 150 minutes. Also the formulation didn’t show any significant changes during 1 month period of stress testing. By virtue of its release pattern and delivering the drug at the right time, right place and in right amounts, the developed delivery system holds good promises of benefiting the patients suffering from peptic ulcers. The release profile of optimized formulation C5 was close to korsmeyer peppas model. Irrespective of the polymer type and its concentration, the prepared optimized pulsatile tablets showed non fickian (anomalous) release.